CorriXR Therapeutics announced a strategic collaboration with InhaTarget Therapeutics and Merxin Ltd to develop an inhaled genetic therapy for lung cancer that delivers treatment directly to tumors to maximize impact while minimizing systemic side effects. The partnership combines CorriXR’s CRISPR-based NRF2 gene-editing platform, InhaTarget’s lipid nanoparticle inhalation formulation capabilities, and Merxin’s inhaler device technology. This milestone demonstrates continued progress toward more targeted and patient-friendly cancer treatments.
Read more here.
Read the press release here.